{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_19116", "batch_size": 200, "batch_pos": 144, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb or potent metaphor.", "method": "llm_batch", "batch_id": "batch_2_15160", "batch_size": 200, "batch_pos": 137, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with scale/impact information.", "method": "llm_batch", "batch_id": "batch_3_3996", "batch_size": 200, "batch_pos": 113, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "Segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_19364", "batch_size": 200, "batch_pos": 111, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment discusses advantages of technology, not providing a calming cue about the current threat.", "method": "llm_batch", "batch_id": "batch_5_6456", "batch_size": 200, "batch_pos": 109, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_5764", "batch_size": 200, "batch_pos": 100, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_16996", "batch_size": 200, "batch_pos": 95, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "uncertain", "rationale": "LLM call failed.", "method": "llm_batch", "batch_id": "batch_8_6524", "batch_size": 200, "batch_pos": 55, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 9, "answer": "no", "rationale": "The segment discusses advantages of technology, which includes positive framing.", "method": "llm_batch", "batch_id": "batch_9_20260", "batch_size": 200, "batch_pos": 125, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 10, "answer": "no", "rationale": "The segment describes advantages of a technology, not speculation about future relief from the threat.", "method": "llm_batch", "batch_id": "batch_10_19676", "batch_size": 200, "batch_pos": 78, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 11, "answer": "no", "rationale": "Attribution 'said' but no direct quote text.", "method": "llm_batch", "batch_id": "batch_11_16436", "batch_size": 200, "batch_pos": 72, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 12, "answer": "yes", "rationale": "Q12 reached. No explicit framing cues found. Facts presented factually.", "method": "llm_batch", "batch_id": "batch_12_19472", "batch_size": 200, "batch_pos": 72, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
